ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Globenewswire
- Investigation Launched: Pomerantz LLP is investigating whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Clinical Trial Data: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome; despite positive framing, the occurrence of adverse events could tarnish the company's reputation.
- Stock Price Reaction: Following the clinical data release, ADC's stock price fell by $0.65, a 14.13% drop, closing at $3.95 per share, reflecting market concerns about the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent securities class action firm with over 85 years of experience, is dedicated to protecting investor rights, and adverse findings from the investigation could result in significant financial liabilities for the company.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.520
Low
5.00
Averages
7.33
High
10.00
Current: 3.520
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








